Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 2 6Phase NA 2Phase 3 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 2Unknown 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2NET 1CNS 1

Conditions

Pheochromocytoma 1Neuroendocrine Tumors 1Neuroblastoma 1Neoplasm Metastasis 1Disease 1

Interventions

Cyclophosphamide 299Cisplatin 298Paclitaxel 257Radiotherapy 255Fluorouracil 234Carboplatin 234Docetaxel 230Doxorubicin 216Dexamethasone 166Gemcitabine 156Vincristine 147Etoposide 136Leucovorin 133Capecitabine 129Bevacizumab 129Prednisone 125Rituximab 118Methotrexate 118Cytarabine 110Filgrastim 99Trastuzumab 97Oxaliplatin 96pembrolizumab 83Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Daunorubicin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Completed × 3-Iodobenzylguanidine × Clear all
NCT00126412 2019-05-31

Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma

GE Healthcare

Phase 3 Completed
251 enrolled
CNSEndocrine

Disease, Neuroblastoma, Pheochromocytoma

NCT00037869 2018-10-31

High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors

M.D. Anderson Cancer Center

Phase 3 Completed
15 enrolled
EndocrineNET

Neoplasm Metastasis, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡